Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

  • Showing results for petoumenos k. Search instead for Petoumenous K (1 item)
1.

Evolution of HIV-1 surveillance drug resistance mutations over ten years in New South Wales, Australia.

Pinto A, Carrera A, Salem H, Thapa K, Shaik A, Petoumenos K, Cunningham P, Garsia R, Dwyer D, Cooper DA, Kelleher AD.

AIDS Res Hum Retroviruses. 2017 May 5. doi: 10.1089/AID.2016.0301. [Epub ahead of print]

PMID:
28474534
2.

CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy.

Petoumenos K, Choi JY, Hoy J, Kiertiburanakul S, Ng OT, Boyd M, Rajasuriar R, Law M; Australian HIV Observational Database; TREATAsia HIV Observational Database.

Antivir Ther. 2017 Mar 14. doi: 10.3851/IMP3155. [Epub ahead of print]

PMID:
28291735
3.

The impact of changes in HIV management guidelines on time to treatment initiation in Australia.

Puhr R, Petoumenos K, Youds D, Law MG, Templeton DJ; Australian HIV Observational Database (AHOD) study group.

HIV Med. 2017 Feb 22. doi: 10.1111/hiv.12504. [Epub ahead of print] No abstract available.

PMID:
28224755
4.

HCV reinfection incidence among individuals treated for recent infection.

Martinello M, Grebely J, Petoumenos K, Gane E, Hellard M, Shaw D, Sasadeusz J, Applegate TL, Dore GJ, Matthews GV.

J Viral Hepat. 2017 May;24(5):359-370. doi: 10.1111/jvh.12666. Epub 2017 Jan 23.

PMID:
28027424
5.

A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol.

Callander D, Stoové M, Carr A, Hoy JF, Petoumenos K, Hellard M, Elliot J, Templeton DJ, Liaw S, Wilson DP, Grulich A, Cooper DA, Pedrana A, Donovan B, McMahon J, Prestage G, Holt M, Fairley CK, McKellar-Stewart N, Ruth S, Asselin J, Keen P, Cooper C, Allan B, Kaldor JM, Guy R.

BMC Infect Dis. 2016 Dec 12;16(1):752.

6.

Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men.

Moore CL, Grulich AE, Prestage G, Gidding HF, Jin F, Petoumenos K, Zablotska IB, Poynten IM, Mao L, Law MG, Amin J.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):589-597.

PMID:
27846072
7.

Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.

Martinello M, Gane E, Hellard M, Sasadeusz J, Shaw D, Petoumenos K, Applegate T, Grebely J, Maire L, Marks P, Dore GJ, Matthews GV.

Hepatology. 2016 Dec;64(6):1911-1921. doi: 10.1002/hep.28844. Epub 2016 Oct 27.

PMID:
27639183
8.

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV.

Antivir Ther. 2016;21(5):465. doi: 10.3851/IMP3073. Epub 2016 Aug 10. No abstract available.

PMID:
27509356
9.

Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons.

Petoumenos K, Law MG.

Curr Opin HIV AIDS. 2016 Sep;11(5):514-520.

PMID:
27327615
10.

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.

Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren JD.

Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18.

PMID:
27090986
11.

Risk factors associated with incident sexually transmitted infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study.

Mulhall BP, Wright ST, De La Mata N, Allen D, Brown K, Dickson B, Grotowski M, Jackson E, Petoumenos K, Foster R, Read T, Russell D, Smith DJ, Templeton DJ, Fairley CK, Law MG.

HIV Med. 2016 Sep;17(8):623-30. doi: 10.1111/hiv.12371. Epub 2016 Mar 28.

PMID:
27019207
12.

Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.

Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV.

Antivir Ther. 2016;21(5):425-34. doi: 10.3851/IMP3035. Epub 2016 Feb 11.

PMID:
26867206
13.

Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men.

Moore CL, Gidding HF, Jin F, Mao L, Petoumenos K, Zablotska IB, Poynten IM, Prestage G, Law MG, Grulich AE, Amin J.

AIDS Behav. 2016 Oct;20(10):2372-86. doi: 10.1007/s10461-016-1303-3.

PMID:
26837635
14.

How do outcomes compare between women and men living with HIV in Australia? An observational study.

Giles ML, Zapata MC, Wright ST, Petoumenos K, Grotowski M, Broom J, Law MG, O'Connor CC.

Sex Health. 2016 Apr;13(2):155-61. doi: 10.1071/SH15124.

PMID:
26827052
15.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
16.

Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort.

Tilley DM, Griggs E, Hoy J, Wright ST, Woolley I, Burke M, O'Connor CC; Australian HIV Observational Database (AHOD).

AIDS Care. 2015;27(11):1410-7. doi: 10.1080/09540121.2015.1113227.

PMID:
26679270
17.

Reducing Viral Load Measurements to Once a Year in Patients on Stable, Virologically Suppressive Cart Regimen: Findings from the Australian HIV Observational Database.

Rafiee M, Kariminia A, Wright S, Mills G, Woolley I, Smith D, Templeton DJ, Law MG, Petoumenos K.

J AIDS Clin Res. 2014 Dec;5(12). pii: 383.

18.

HIV-infection and comorbidities: a complex mix.

Petoumenos K, Law M.

Lancet HIV. 2015 Jul;2(7):e265-6. doi: 10.1016/S2352-3018(15)00082-X. Epub 2015 May 27. No abstract available.

PMID:
26423249
19.

Hospitalisation rates and associated factors in community-based cohorts of HIV-infected and -uninfected gay and bisexual men.

Moore CL, Grulich AE, Prestage G, Gidding HF, Jin F, Mao L, Petoumenos K, Zablotska IB, Poynten IM, Law MG, Amin J.

HIV Med. 2016 May;17(5):327-39. doi: 10.1111/hiv.12312. Epub 2015 Sep 6.

20.

Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions.

Cornall AM, Roberts JM, Molano M, Machalek DA, Phillips S, Hillman RJ, Grulich AE, Jin F, Poynten IM, Templeton DJ, Garland SM, Tabrizi SN; SPANC Study Team.

BMJ Open. 2015 Aug 26;5(8):e008439. doi: 10.1136/bmjopen-2015-008439.

Supplemental Content

Loading ...
Support Center